Zoetis Inc. (NYSE:ZTS) Shares Sold by Howland Capital Management LLC

Howland Capital Management LLC lessened its position in Zoetis Inc. (NYSE:ZTSFree Report) by 2.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,797 shares of the company’s stock after selling 91 shares during the period. Howland Capital Management LLC’s holdings in Zoetis were worth $749,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of ZTS. Norges Bank bought a new position in Zoetis in the 4th quarter valued at about $745,861,000. Morgan Stanley grew its position in Zoetis by 34.6% in the 4th quarter. Morgan Stanley now owns 10,872,704 shares of the company’s stock valued at $1,593,395,000 after buying an additional 2,796,694 shares in the last quarter. Moneta Group Investment Advisors LLC grew its position in Zoetis by 124,281.9% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 2,332,160 shares of the company’s stock valued at $341,778,000 after buying an additional 2,330,285 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its position in Zoetis by 171.7% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 3,326,448 shares of the company’s stock valued at $627,335,000 after buying an additional 2,102,306 shares in the last quarter. Finally, Vaughan Nelson Investment Management L.P. bought a new position in Zoetis in the 3rd quarter valued at about $176,219,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. The Goldman Sachs Group raised their price objective on shares of Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a research report on Wednesday, January 17th. StockNews.com lowered shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Jefferies Financial Group restated a “buy” rating and set a $230.00 price objective on shares of Zoetis in a research report on Tuesday, December 19th. Stifel Nicolaus reduced their price objective on shares of Zoetis from $215.00 to $195.00 and set a “buy” rating for the company in a research report on Tuesday. Finally, Barclays raised their price objective on shares of Zoetis from $255.00 to $260.00 and gave the company an “overweight” rating in a research report on Wednesday, February 14th. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat, Zoetis currently has an average rating of “Buy” and an average price target of $222.11.

Get Our Latest Analysis on Zoetis

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of the business’s stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $173.33, for a total value of $159,983.59. Following the completion of the sale, the executive vice president now directly owns 15,723 shares of the company’s stock, valued at $2,725,267.59. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 2,209 shares of company stock valued at $408,453 over the last ninety days. Corporate insiders own 0.15% of the company’s stock.

Zoetis Stock Down 0.0 %

Zoetis stock traded down $0.03 during trading hours on Wednesday, hitting $164.98. The company had a trading volume of 235,043 shares, compared to its average volume of 2,680,550. The firm has a market capitalization of $75.46 billion, a P/E ratio of 32.55, a price-to-earnings-growth ratio of 2.55 and a beta of 0.85. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.36 and a quick ratio of 2.00. The firm’s fifty day moving average is $184.62 and its 200-day moving average is $181.88. Zoetis Inc. has a fifty-two week low of $151.03 and a fifty-two week high of $201.92.

Zoetis (NYSE:ZTSGet Free Report) last released its quarterly earnings data on Tuesday, February 13th. The company reported $1.24 earnings per share for the quarter, missing the consensus estimate of $1.32 by ($0.08). The company had revenue of $2.21 billion during the quarter, compared to analyst estimates of $2.19 billion. Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The firm’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.15 EPS. On average, research analysts forecast that Zoetis Inc. will post 5.8 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be given a $0.432 dividend. This represents a $1.73 annualized dividend and a yield of 1.05%. The ex-dividend date of this dividend is Thursday, April 18th. Zoetis’s dividend payout ratio is 34.12%.

About Zoetis

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Featured Articles

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSFree Report).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.